
NYSE:CL
This summary was created by AI, based on 2 opinions in the last 12 months.
Colgate-Palmolive (CL) has garnered positive attention as analysts recommend buying the stock at its 52-week lows, paired with a modest 2.5% dividend yield. Despite enduring a challenging year for consumer staples, the company's latest performance has shown resilience, with CL surpassing both revenue and earnings expectations. The supply chain is showing signs of improvement, although there are lingering concerns regarding tariff-related costs, which have seen a reduction from an initial estimate of $200 million to $75 million. Analysts remain optimistic about the company's long-term prospects, highlighting its ability to navigate current market challenges while maintaining operational efficiency and profitability.
He is avoiding staples right now. They are trading very, very rich. This company has had a negative earnings revision and are really struggling in some of their core categories with pricing pressures and volume. Not a lot of positive things to say about this. He would be moving on to a different sector, on the view that we will be seeing higher rates. This is not a “Growth” story, it is a “how do we save the ship” story.
Probably one of the better staple companies. In July it had a big Venezuelan devaluation which resulted in a sharp drop in earnings. This was followed by the currency earnings drag. You are going to probably see some pullbacks and corrections in valuations, but longer-term this is a very good story if you have a multi-year view on the company.
A consumer brand business. The issue is that 80% of revenue is from outside of North America. 21 times earnings and a good dividend yield. Another issue is that they have good brand loyalty but they are known for their toothpaste. He would prefer they sold off Hills, the veterinary business. This company performs well over the long term so if you have a long time horizon then buy on a pull back. They increase dividends regularly.
Colgate Palmolive is a American stock, trading under the symbol CL (previously CL-N on Stockchase) on the New York Stock Exchange (CL). It is usually referred to as NYSE:CL or CL
In the last year, 2 stock analysts published opinions about CL (previously CL-N on Stockchase). 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for Colgate Palmolive.
Colgate Palmolive was recommended as a Top Pick by Norman Levine on 2014-12-04. Read the latest stock experts ratings for Colgate Palmolive.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Colgate Palmolive in the last year. It is a trending stock that is worth watching.
On 2026-06-09, Colgate Palmolive (CL) stock closed at a price of $87.80.
Buy it now at 52-week lows and ride the 2.5% dividend.